Skip to main content

Idexx Laboratories Inc. Value Stock - Dividend - Research Selection

Idexx

ISIN: US45168D1046 , WKN: 888210

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)

2025-11-21
Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

What Are Wall Street Analysts' Target Price for IDEXX Laboratories Stock?

2025-11-21
IDEXX Laboratories has considerably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

How the Story Around IDEXX Is Shifting With Strong Results and New Analyst Targets

2025-11-20
The consensus analyst price target for IDEXX Laboratories has recently increased from $702.17 to $754.83. This underscores renewed optimism following a strong quarterly report and an improved outlook for 2025. The uptick reflects analysts’ confidence in the company’s growth prospects and effective management execution. Stay tuned to learn the key factors driving these price target updates and how you can remain informed as the narrative continues to evolve. Stay updated as the Fair Value for...

Bruker Stock Earns Relative Strength Rating Upgrade

2025-11-20
Bruker stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 68 to 72.   Can You Really Time The Stock Market? This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average

2025-11-20
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Pet Healthcare Spending Is Soaring. These 5 Stocks Are Positioned to Clean Up

2025-11-14
The steep increase in pet healthcare costs have doubled over the past five years, according to NPR. There are a number of reasons for this trend, but the overall numbers are large, reaching $39.8 billion in 2024. Some projections estimate that pet healthcare will swell to $112 billion by 2030. As a result, veterinary healthcare ... Pet Healthcare Spending Is Soaring. These 5 Stocks Are Positioned to Clean Up

Baron Asset Fund Q3 2025 Performance Review

2025-11-13
Baron Asset Fund underperformed for a second consecutive quarter as U.S. equities continued their strong rally from the market lows reached on April 8. Read more here.

Baron Asset Fund Q3 2025 Shareholder Letter

2025-11-13
Baron Asset Fund declined in the third quarter and trailed its index, the Russell Midcap Growth Index. Read more here.

Here’s Why IDEXX Laboratories (IDXX) Surged in Q3

2025-11-10
Baron Funds, an investment management company, released its “Baron Asset Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. US equities continued the previous quarter’s rally in the third quarter of 2025. The expectation of the Federal Reserve (the Fed) to cut interest rates was the primary driver behind the […]

Why IDEXX Laboratories (IDXX) Is Up 13.6% After Strong Q3 Results and Raised 2025 Guidance

2025-11-07
IDEXX Laboratories recently reported strong third-quarter results, with revenue of US$1,105.24 million and net income of US$274.61 million, as well as raising its full-year 2025 revenue and EPS guidance on the back of robust growth in Companion Animal Diagnostics and successful new product launches. The company also completed a buyback tranche repurchasing 411,180 shares for US$241.57 million in the quarter, highlighting continued commitment to capital returns amid expanding margins and...